Senate advances sweeping implementation fixes to Utah medical cannabis law

The Utah Senate on Feb. 24 approved Second Substitute Senate Bill 121, a broad set of changes intended to finish implementing the state''s medical cannabis program.

Sponsor Senator Vickers said the bill clarifies packaging options, permits the Department of Agriculture to perform interim product testing until two licensed independent labs are operating, and adjusts patient and cultivation rules to ensure product availability as the program scales up. "We don't have enough testing labs right now," Vickers said, explaining that the Department of Agriculture has existing funds and can perform testing temporarily until private labs are licensed.

The changes also increase physician patient caps, raising the general practitioner cap from 175 to 275 and a specialist cap from 300 to 600, and allow cultivators who used short-term production sites to retain both sites provided total square footage limits remain. The bill permits telehealth for renewal visits, clarifies that private employers may maintain independent workplace policies, and creates a process for licensees to disclose out-of-state investigations within 14 days.

Senator Hilliard asked about clinical testing of cannabis as a treatment; Vickers pointed to University of Utah studies and the Cannabinoid Product Review Board''led by Dr. Ed Redd''to collect data and report on outcomes. The bill also includes provisions on packaging (secure sealed containers), pharmacy-to-pharmacy transfers, and protections for FDA-approved cannabinoid products.

Under suspension of the rules the Senate passed the measure on a recorded vote. The measure now goes to the House for consideration or concurrence on the substituted language. The sponsor said several technical points remain tied to implementation timelines, including when independent testing capacity is expected to come online.